Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
Open Access
- 17 January 2023
- journal article
- review article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (1)
- https://doi.org/10.1177/03000605221149870
Abstract
ObjectiveTo conduct a meta-analysis assessing the efficacy and safety of cyclosporine-based combinations for primary immune thrombocytopenia (ITP). MethodsRandomized controlled clinical trials were collected by systematically searching databases (PubMed (R), MEDLINE (R), EMBASE, The Cochrane Library, China National Knowledge Infrastructure) from inception to June 2022. All studies included patients with ITP who received cyclosporine-based regimens. We performed comprehensive analyses of the overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, relapse rate, platelet count, and adverse drug reaction (ADR) rate. ResultsSeven studies (n = 418) were ultimately included. According to a fixed-effects model, cyclosporine-based combinations improved the ORR and CR rate and reduced the relapse rate. The ADR rate was not increased in the cyclosporine-based combination group. Cyclosporine-based regimens effectively increased the platelet count. Subgroup analysis illustrated that cyclosporine-based combinations were linked to higher ORRs in both children (odds ratio [OR] = 5.74, 95% confidence interval [CI] = 1.79-18.41) and adults (OR = 5.46, 95% CI = 2.48-12.02) and a higher CR rate in adults (OR = 2.97, 95% CI = 1.56-5.63). ConclusionCyclosporine exhibited efficacy in the treatment of ITP without increasing the risk of ADRs.Keywords
This publication has 29 references indexed in Scilit:
- Cyclosporin A for persistent or chronic immune thrombocytopenia in childrenAnnals of Hematology, 2016
- The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2016
- Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for FcγRIIB falls by the waysideSeminars in Hematology, 2016
- Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reportsClinical Case Reports, 2015
- T cell immune abnormalities in immune thrombocytopeniaJournal of Hematology & Oncology, 2014
- Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia.2013
- Defective regulatory B-cell compartment in patients with immune thrombocytopeniaBlood, 2012
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Epidemiology of immune thrombocytopenic purpura in the General Practice Research DatabaseBritish Journal of Haematology, 2009